Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin A nephropathy

Abstract

Background: Immunoglobulin A nephropathy (IgAN) is the most prevalent form of glomerulonephritis worldwide. Prediction of disease progression in IgAN can help to provide individualized treatment based on accurate risk stratification. Methods: We performed proton nuclear magnetic resonance-based metabolomics analyses of serum and urine samples from healthy controls, non-progressor (NP), and progressor (P) groups to identify metabolic profiles of IgAN disease progression. Metabolites that were significantly different between the NP and P groups were selected for pathway analysis. Subsequently, we analyzed multivariate area under the receiver operating characteristic (ROC) curves to evaluate the predictive power of metabolites associated with IgAN progression. Results: We observed several distinct metabolic fingerprints of the P group involving the following metabolic pathways: glycolipid metabolism; valine, leucine, and isoleucine biosynthesis; aminoacyl-transfer RNA biosynthesis; glycine, serine, and threonine metabolism; and glyoxylate and dicarboxylate metabolism. In multivariate ROC analyses, the combinations of serum glycerol, threonine, and proteinuria (area under the curve [AUC], 0.923; 95% confidence interval [CI], 0.667–1.000) and of urinary leucine, valine, and proteinuria (AUC, 0.912; 95% CI, 0.667–1.000) showed the highest discriminatory ability to predict IgAN disease progression. Conclusion: This study identified serum and urine metabolites profiles that can aid in the identification of progressive IgAN and proposed perturbed metabolic pathways associated with the identified metabolites.

Metabolomics profiling: a potential tool for predicting immunoglobulin A nephropathy progression

“…Moreover, variability in urine metabolite concentrations due to diet, lifestyle, volume status, medications, and other factors necessitates rigorous study design and data normalization strategies. Jeon et al [7] investigated the metabolomic profiles in the serum and urine of patients with IgAN to identify potential biomarkers for disease progression. The study included 20 IgAN patients, of whom a proportion exhibited disease progression, with higher urine protein/creatinine ratios than the non-progressor group.…”